The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a generic version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.
Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.
British drugmaker GSK and Chinese biotech Clover Biopharmaceuticals have partnered to develop a protein-based coronavirus vaccine candidate.
US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.
Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
The UK Intellectual Property Office and the Chartered Institute of Patent Attorneys have worked together to ensure changes are made to “misleading” advice issued by the EU’s Community Plant Variety Office.
Arnold & Porter partner Richard Dickinson has joined Bristows as a partner in its commercial and IP transactional practice in London.
Jason Markwell, a former partner at Belmore Neidrauer, has joined Fasken’s IP group in its Toronto office.
A life sciences litigator from Williams & Connolly has joined Latham & Watkins’ Washington, DC office.